LNTH - Lantheus Holdings

-

$undefined

N/A

(N/A)

Lantheus Holdings NasdaqGM:LNTH Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Location: 201 Burlington Road, Bedford, MA, 01730, United States | Website: https://www.lantheus.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

4.901B

Cash

938.5M

Avg Qtr Burn

N/A

Short % of Float

12.75%

Insider Ownership

2.29%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
RELISTOR Details
Constipation

Approved

Quarterly sales

Approved

Quarterly sales

AZEDRA® (iobenguane I 131) Details
Pheochromocytoma , Paraganglioma , Solid tumor/s

Approved

Quarterly sales

DEFINITY® Room Temperature Details
Suboptimal echocardiograms

Approved

Quarterly sales

Flurpiridaz F 18 Details
Heart disease, Coronary artery disease

NDA

Acceptance for review

NDA

Submission

¹⁷⁷Lu-PNT2002 Details
Cancer, Castration-resistant prostate cancer

Phase 3

Update

Phase 3

Update

Phase 2

Data readout

¹⁷⁷Lu-DOTA-RM2 Details
Cancer, Prostate cancer

Phase 1/2

Initiation

LNTH-1404 Details
Prostate cancer, Cancer

Failed

Discontinued